local_hospital

Ippokratio General Hospital Of Thessaloniki

Address
lock Available on a paid plan

Eye Diseases and Ophthalmology

At Ippokratio General Hospital Of Thessaloniki, the Ophthalmology Clinic is active in research on eye diseases such as glaucoma, ocular hypertension, and thyroid eye disease. These studies are focused on improving diagnosis, testing better treatment options, and evaluating how well therapies protect vision over time.

  • Glaucoma and elevated intraocular pressure
  • Ocular hypertension and vision preservation
  • Thyroid eye disease and immune-related eye inflammation

The site also contributes to trials assessing whether new or improved eye treatments can offer reliable control of eye pressure and better long-term outcomes for patients.

Dermatology and Immune-Mediated Skin Disease

A major part of the research portfolio covers skin and connective tissue diseases, especially atopic dermatitis, psoriasis, hidradenitis suppurativa, prurigo nodularis, and bullous pemphigoid. These trials are designed to test new therapies, improve symptom control, and understand long-term safety in chronic inflammatory skin conditions.

  • Atopic dermatitis and persistent itching
  • Psoriasis and plaque control
  • Hidradenitis suppurativa and chronic skin inflammation

The research at this hospital often explores whether emerging treatments can reduce disease activity, relieve discomfort, and maintain benefits over time in patients with difficult-to-manage dermatologic conditions.

Gastroenterology, Liver Disease, and Inflammatory Bowel Disease

The site conducts studies in digestive system diseases and nutritional and metabolic diseases, with a strong focus on Crohn’s disease, ulcerative colitis, eosinophilic esophagitis, NASH, and non-alcoholic fatty liver disease. This work aims to improve treatment effectiveness, reduce inflammation, and support better long-term disease control.

  • Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis
  • NASH and liver fibrosis
  • Eosinophilic esophagitis and swallowing-related symptoms

Research in this area reflects a broad effort to find therapies that can slow disease progression, improve quality of life, and address chronic gastrointestinal and liver inflammation.

Kidney, Cardiovascular, and Metabolic Disorders

Clinical trials at Ippokratio General Hospital Of Thessaloniki also cover cardiovascular diseases, chronic kidney disease, heart failure, hypertension, and type 2 diabetes. These studies are aimed at evaluating treatments that may protect kidney function, improve heart outcomes, and better manage blood pressure and metabolic risk.

  • Chronic kidney disease and proteinuria
  • Heart failure and cardiovascular risk
  • Hypertension and metabolic disease

The research landscape here includes efforts to test therapies that could delay organ damage, reduce complications, and support more effective long-term management of interconnected heart, kidney, and metabolic conditions.

Infectious Diseases and Antimicrobial Research

Another active area involves bacterial infections, virus diseases, fungal infections, and serious hospital-based infections such as sepsis, pneumonia, and urinary tract infections. These trials are focused on improving treatment effectiveness, supporting faster infection control, and addressing difficult-to-treat pathogens.

  • Sepsis and bloodstream infection
  • Complicated urinary tract and intra-abdominal infections
  • Invasive candidiasis and other fungal infections

The hospital contributes to research that helps refine infection treatment strategies, particularly for patients with severe illness or infections that require specialized care.

Rare Diseases, Hematology, and Pediatric Conditions

The site is also involved in trials for hemic and lymphatic diseases, congenital disorders, and other rare conditions, including thalassemia, hemophilia, sickle cell disease, and juvenile idiopathic arthritis. These studies often aim to improve disease control, reduce complications, and evaluate new approaches for long-term care.

  • Thalassemia and anemia-related disorders
  • Hemophilia and bleeding prevention
  • Pediatric inflammatory and genetic diseases

This area of research highlights the hospital’s role in studying uncommon and complex diseases where better therapies can make a substantial difference for patients and families.

Site Overview

assignment
153
connected trials
corporate_fare
67
sponsors
science
247
IMPs

Activity Indicator

Last 6 months

14
Trials started
+56% vs previous period.
9
Trials started 6–12 months ago
153
Total trials linked
Highly Active
trending_upGrowing+56%
1
1
4
5
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 19 therapeutic areas and 15 of 247 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 232 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
71
Sponsors (total)
67
Active sponsors
48

Sponsor Network

Top 48 by active trials.

lock +47 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +25 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 173 other sites in Greece

description
Trial volume
153
Outperforms 95% of sites
public
Therapeutic diversity
19areas
Outperforms 96% of sites
groups
Sponsor diversity
67sponsors
Outperforms 95% of sites

Therapeutic Area Benchmark — Greece

Select a therapeutic area to compare against other sites in Greece.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Greece

Market Share

Country: Greece

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Ippokratio General Hospital Of Thessaloniki

lock Showing 1 of 153 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Comparative Study of Somapacitan and Somatropin in Pediatric Patients with Short Stature Due to SGA, Turner Syndrome, Noonan Syndrome, or Idiopathic Short StatureNovo Nordisk A/SPhase IIINot RecruitingAug 2022

IMP list

lock Showing 1 of 247 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Etoposide6Unknown2015-06-022024-11-21

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.